Heinz Zoller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8040163/publications.pdf

Version: 2024-02-01

63
ndex
5149
7177
authors

#	Article	IF	Citations
1	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	1.8	282
2	Autocrine formation of hepcidin induces iron retention in human monocytes. Blood, 2008, 111, 2392-2399.	0.6	255
3	Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia. JAMA - Journal of the American Medical Association, 2020, 323, 432.	3.8	162
4	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	1.8	149
5	Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism: Clinical and Experimental, 2016, 65, 1151-1160.	1.5	143
6	Dietary lipids fuel GPX4-restricted enteritis resembling Crohn's disease. Nature Communications, 2020, 11, 1775.	5.8	143
7	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. Frontiers in Immunology, 2019, 10, 476.	2.2	134
8	A time-resolved proteomic and prognostic map of COVID-19. Cell Systems, 2021, 12, 780-794.e7.	2.9	125
9	Ferroportin disease: A systematic meta-analysis of clinical and molecular findings. Journal of Hepatology, 2010, 53, 941-949.	1.8	121
10	Iron-induced hypophosphatemia. Current Opinion in Nephrology and Hypertension, 2017, 26, 266-275.	1.0	121
11	Reduced sodium/proton exchanger NHE3 activity causes congenital sodium diarrhea. Human Molecular Genetics, 2015, 24, 6614-6623.	1.4	111
12	Austrian consensus guidelines on the management and treatment of portal hypertension (BillrothÂIII). Wiener Klinische Wochenschrift, 2017, 129, 135-158.	1.0	111
13	Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease. Hepatology, 2019, 69, 1464-1476.	3.6	110
14	Iron supplementation in athletesâ€"first do no harm. Nutrition, 2004, 20, 615-619.	1.1	106
15	Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. Gastroenterology, 2019, 157, 705-719.e18.	0.6	82
16	Patatin-Like Phospholipase Domain-Containing Protein 3 rs738409-G in Recipients of Liver Transplants Is a Risk Factor for Graft Steatosis. Clinical Gastroenterology and Hepatology, 2013, 11, 1667-1672.	2.4	81
17	Congenital secretory diarrhoea caused by activating germline mutations in <i>GUCY2C </i> . Gut, 2016, 65, 1306-1313.	6.1	74
18	DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transplant International, 2016, 29, 999-1007.	0.8	73

#	Article	IF	CITATIONS
19	EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH). European Journal of Human Genetics, 2016, 24, 479-495.	1.4	73
20	Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk. PLoS ONE, 2016, 11, e0167146.	1.1	68
21	Systemic inflammation as fuel for acute liver injury in COVID-19. Digestive and Liver Disease, 2021, 53, 158-165.	0.4	63
22	Stereotactic Radiofrequency Ablation of Hepatocellular Carcinoma: a Histopathological Study in Explanted Livers. Hepatology, 2019, 70, 840-850.	3 . 6	61
23	Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2021, 87, 2256-2273.	1.1	61
24	Hepcidin messenger RNA expression in human lymphocytes. Immunology, 2010, 130, 217-230.	2.0	59
25	R2* Relaxometry for the Quantification of Hepatic Iron Overload: Biopsy-Based Calibration and Comparison with the Literature. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2015, 187, 472-479.	0.7	59
26	Heterozygosity for the alphaâ€1â€antitrypsin Z allele in cirrhosis is associated with more advanced disease. Liver Transplantation, 2018, 24, 744-751.	1.3	58
27	Identification of Mutations in SLC40A1 That Affect Ferroportin Function and Phenotype of Human Ferroportin Iron Overload. Gastroenterology, 2011, 140, 2056-2063.e1.	0.6	57
28	Primary iron overload with inappropriate hepcidin expression in $V162$ del ferroportin disease. Hepatology, 2005, 42, 466-472.	3.6	54
29	Followâ€up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirinâ€free treatment. Liver International, 2018, 38, 1028-1035.	1.9	51
30	Duodenal cytochrome B and hephaestin expression in patients with iron deficiency and hemochromatosis. Gastroenterology, 2003, 125, 746-754.	0.6	50
31	Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. British Journal of Haematology, 2009, 144, 789-793.	1.2	49
32	EASL Clinical Practice Guidelines on haemochromatosis. Journal of Hepatology, 2022, 77, 479-502.	1.8	49
33	Direct Measurement of ATP7B Peptides Is Highly Effective in the Diagnosis of Wilson Disease. Gastroenterology, 2021, 160, 2367-2382.e1.	0.6	48
34	Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the <scp>MNGIE</scp> International Network. Journal of Inherited Metabolic Disease, 2021, 44, 376-387.	1.7	47
35	Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Alimentary Pharmacology and Therapeutics, 2019, 50, 397-406.	1.9	46
36	Responseâ€guided longâ€ŧerm treatment of chronic hepatitis D patients with bulevirtide—results of a "real world―study. Alimentary Pharmacology and Therapeutics, 2022, 56, 144-154.	1.9	46

#	Article	IF	CITATIONS
37	Intravenous iron supplementation therapy. Molecular Aspects of Medicine, 2020, 75, 100862.	2.7	44
38	Static cold storage compared with normothermic machine perfusion of the liver and effect on ischaemic-type biliary lesions after transplantation: a propensity score-matched study. British Journal of Surgery, 2021, 108, 1082-1089.	0.1	43
39	Classical and intermediate monocytes scavenge non-transferrin-bound iron and damaged erythrocytes. JCl Insight, 2019, 4, .	2.3	42
40	3D Multiecho Dixon for the Evaluation of Hepatic Iron and Fat in a Clinical Setting. Journal of Magnetic Resonance Imaging, 2017, 46, 793-800.	1.9	40
41	Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management. Bone, 2022, 154, 116202.	1.4	40
42	Indications for liver transplantation in adults. Wiener Klinische Wochenschrift, 2016, 128, 679-690.	1.0	39
43	Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety. Expert Opinion on Drug Safety, 2021, 20, 757-769.	1.0	39
44	Excellent postâ€transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. Liver International, 2016, 36, 688-695.	1.9	38
45	[68Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2005-2013.	3.3	38
46	Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. Human Pathology, 2007, 38, 1057-1064.	1.1	37
47	Hemochromatosis: Genetic Testing and Clinical Practice. Clinical Gastroenterology and Hepatology, 2005, 3, 945-958.	2.4	36
48	Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy. Blood Cells, Molecules, and Diseases, 2012, 48, 233-237.	0.6	33
49	The dilemma to diagnose Wilson disease by genetic testing alone. European Journal of Clinical Investigation, 2019, 49, e13147.	1.7	33
50	Iron metabolism in transplantation. Transplant International, 2014, 27, 1109-1117.	0.8	32
51	Control of iron metabolism – Lessons from neonatal hemochromatosis. Journal of Hepatology, 2012, 56, 1226-1229.	1.8	30
52	Impaired hepcidin expression in alpha-1-antitrypsin deficiency associated with iron overload and progressive liver disease. Human Molecular Genetics, 2015, 24, 6254-6263.	1.4	30
53	Interferon-Alpha Therapy in Patients with Hepatitis C Virus Infection Increases Plasma Phenylalanine and the Phenylalanine to Tyrosine Ratio. Journal of Interferon and Cytokine Research, 2012, 32, 216-220.	0.5	28
54	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. Gut, 2022, 71, 415-423.	6.1	28

#	Article	IF	Citations
55	A proteomic survival predictor for COVID-19 patients in intensive care., 2022, 1, e0000007.		28
56	Transferrin as a predictor of survival in cirrhosis. Liver Transplantation, 2018, 24, 343-351.	1.3	27
57	Impact of patatinâ€like phospholipase domain containing <i>3 rs738409</i> Â <i>G/G</i> genotype on hepatic decompensation and mortality in patients with portal hypertension. Alimentary Pharmacology and Therapeutics, 2018, 48, 451-459.	1.9	26
58	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. Journal of Hepatology, 2021, 74, 801-810.	1.8	26
59	Cystatin <scp>C</scp> is a strong predictor of survival in patients with cirrhosis: is a cystatin <scp>C</scp> â€based MELD better?. Liver International, 2012, 32, 1211-1216.	1.9	25
60	Performance of different Dixon-based methods for MR liver iron assessment in comparison to a biopsy-validated R2* relaxometry method. European Radiology, 2021, 31, 2252-2262.	2.3	25
61	Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by a novel ferroportin mutation. Hepatology, 2010, 51, NA-NA.	3.6	24
62	Preoperative Assessment of Muscle Mass Using Computerized Tomography Scans to Predict Outcomes Following Orthotopic Liver Transplantation. Transplantation, 2019, 103, 2506-2514.	0.5	24
63	Liver disease in adults with α1â€antitrypsin deficiency. United European Gastroenterology Journal, 2018, 6, 710-718.	1.6	23
64	Effects of 24h working on-call on psychoneuroendocrine and oculomotor function: A randomized cross-over trial. Psychoneuroendocrinology, 2014, 47, 221-231.	1.3	22
65	Blood and Bone Loser. Gastroenterology, 2017, 152, e5-e6.	0.6	20
66	Hepatocellular carcinoma: when is liver transplantation oncologically futile? Translational Gastroenterology and Hepatology, 2017, 2, 63-63.	1.5	20
67	Hepatitis C virus eradication with directâ€acting antiviral improves insulin resistance. Journal of Viral Hepatitis, 2020, 27, 188-194.	1.0	20
68	Liver stiffness by transient elastography accompanies illness severity in COVID-19. BMJ Open Gastroenterology, 2020, 7, e000445.	1.1	20
69	Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1009-1019.	1.8	20
70	Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis. United European Gastroenterology Journal, 2021, 9, 1119-1127.	1.6	20
71	Evaluation of liver fat in the presence of iron with MRI using T2* correction: a clinical approach. European Radiology, 2013, 23, 1643-1649.	2.3	19
72	Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1406-1412.	1.8	18

#	Article	IF	CITATIONS
73	Con: Liver transplantation for expanded criteria malignant diseases. Liver Transplantation, 2018, 24, 104-111.	1.3	18
74	Pathogenesis, Diagnosis and Treatment of Hemochromatosis. Digestive Diseases, 2016, 34, 364-373.	0.8	15
75	HSD17B13 truncated variant is associated with a mild hepatic phenotype in Wilson's Disease. JHEP Reports, 2019, 1, 2-8.	2.6	13
76	Interleukin-11 drives human and mouse alcohol-related liver disease. Gut, 2023, 72, 168-179.	6.1	13
77	CFTR gene mutations in pancreatitis: Frequency and clinical manifestations in an Austrian patient cohort. Wiener Klinische Wochenschrift, 2007, 119, 527-533.	1.0	12
78	Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1619-1627.	1.4	12
79	Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study. Clinical Gastroenterology and Hepatology, 2023, 21, 978-987.e2.	2.4	12
80	Hypophosphatemia in children treated with ferric carboxymaltose. Acta Paediatrica, International Journal of Paediatrics, 2020, 109, 1491-1492.	0.7	11
81	Diagnosis of Hepatic Iron Overload. Diagnostic Molecular Pathology, 2009, 18, 53-60.	2.1	10
82	Quantification of liver iron overload disease with laser ablation inductively coupled plasma mass spectrometry. BMC Medical Imaging, 2018, 18, 51.	1.4	10
83	Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease. Liver International, 2020, 40, 1941-1951.	1.9	10
84	Saccadic latency in hepatic encephalopathy: a pilot study. Metabolic Brain Disease, 2010, 25, 285-295.	1.4	9
85	First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: Complete remission followed by lethal sepsis. Liver Transplantation, 2014, 20, 1145-1148.	1.3	9
86	Variants in <i>PCSK7, PNPLA3</i> and <i>TM6SF2</i> are risk factors for the development of cirrhosis in hereditary haemochromatosis. Alimentary Pharmacology and Therapeutics, 2021, 53, 830-843.	1.9	9
87	Longâ€ŧerm followâ€up of ribavirinâ€free <scp>DAA</scp> â€based treatment in <scp>HCV</scp> recurrence after orthotopic liver transplantation. Liver International, 2018, 38, 1188-1197.	1.9	8
88	MRIâ€Based Iron Phenotyping and Patient Selection for Nextâ€Generation Sequencing of Non–Homeostatic Iron Regulator Hemochromatosis Genes. Hepatology, 2021, 74, 2424-2435.	3.6	8
89	The Need to Update Endpoints and Outcome Analysis in the Rapidly Changing Field of Liver Transplantation. Transplantation, 2022, 106, 938-949.	0.5	8
90	R2*-relaxometry of the pancreas in patients with human hemochromatosis protein associated hereditary hemochromatosis. European Journal of Radiology, 2017, 89, 149-155.	1.2	7

#	Article	IF	CITATIONS
91	Letter: inconsistency in reporting of hypophosphatemia after intravenous iron. Alimentary Pharmacology and Therapeutics, 2017, 46, 641-643.	1.9	7
92	Does gadoxetate disodium affect MRE measurements in the delayed hepatobiliary phase?. European Radiology, 2019, 29, 829-837.	2.3	7
93	MR elastography in patients with suspected diffuse liver disease at 1.5T: Intraindividual comparison of gradient-recalled echo versus spin-echo echo-planar imaging sequences and investigation of potential confounding factors. European Journal of Radiology, 2021, 142, 109898.	1.2	7
94	Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism. Pharmaceuticals, 2015, 8, 337-350.	1.7	6
95	CCBE1 mutation causing sclerosing cholangitis: Expanding the spectrum of lymphedemaâ€cholestasis syndrome. Hepatology, 2017, 66, 286-288.	3.6	6
96	Liver transplantation for hilar cholangiocarcinoma (h-CCA): is it the right time?. Translational Gastroenterology and Hepatology, 2018, 3, 38-38.	1.5	6
97	Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030. PLoS ONE, 2018, 13, e0200750.	1.1	6
98	Coronary atherosclerosis profile in patients with end-stage liver disease prior to liver transplantation due to alcoholic fatty liver: a coronary CTA study. European Radiology, 2021, 31, 494-503.	2.3	6
99	Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans. Gut, 2021, 70, 585-594.	6.1	6
100	Neurodegeneration in Hepatic and Neurologic Wilson's Disease. Hepatology, 2021, 74, 1117-1120.	3.6	6
101	Reassessment of Relevance and Predictive Value of Parameters Indicating Early Graft Dysfunction in Liver Transplantation: AST Is a Weak, but Bilirubin and INR Strong Predictors of Mortality. Frontiers in Surgery, 2021, 8, 693288.	0.6	6
102	Synonymous mutation in adenosine triphosphatase copperâ€transporting beta causes enhanced exon skipping in Wilson disease. Hepatology Communications, 2022, 6, 1611-1619.	2.0	6
103	Management of patients with chronic hepatitis C failing repeated courses of interferonâ€free direct acting antiviral combination therapy. GastroHep, 2019, 1, 76-83.	0.3	5
104	Evaluation of liver iron overload with R2* relaxometry with versus without fat suppression: both are clinically accurate but there are differences. European Radiology, 2020, 30, 5826-5833.	2.3	5
105	Should C282Y homozygotes with mild iron overload be treated?. Journal of Hepatology, 2015, 62, 510-511.	1.8	4
106	Letter: retreatment of patients with chronic hepatitis C who have failed interferonâ€free combination therapy with direct acting antiâ€virals. Alimentary Pharmacology and Therapeutics, 2017, 45, 373-375.	1.9	4
107	Iron Matryoshka—Haemochromatosis nested in Ferroportin Disease?. Liver International, 2019, 39, 1014-1015.	1.9	4
108	Highly Elevated Plasma γâ€Glutamyltransferase Elevations: A Trait Caused by γâ€Glutamyltransferase 1 Transmembrane Mutations. Hepatology, 2020, 71, 1124-1127.	3.6	4

#	Article	IF	CITATIONS
109	Advanced Microscopy for Liver and Gut Ultrastructural Pathology in Patients with MVID and PFIC Caused by MYO5B Mutations. Journal of Clinical Medicine, 2021, 10, 1901.	1.0	4
110	Afamin predicts the prevalence and incidence of nonalcoholic fatty liver disease. Clinical Chemistry and Laboratory Medicine, 2021, .	1.4	4
111	Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: A long-term follow-up study. Annals of Hepatology, 2022, 27, 100683.	0.6	4
112	A rare case of Epsteinâ€Barr virusâ€associated hepatosplenic smooth muscle tumors after kidney transplantation. Transplant Infectious Disease, 2018, 20, e12860.	0.7	3
113	Expression of MICA in Zero Hour Biopsies Predicts Graft Survival After Liver Transplantation. Frontiers in Immunology, 2021, 12, 606146.	2.2	3
114	Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV? focus on pegylated interferon-alpha. International Journal of Nanomedicine, 2006, 1, 399-409.	3.3	3
115	Retrospective angiographic study to determine the effect of atherosclerotic stenoses of upstream arteries on the degree of atherosclerosis in distal vascular territories. BMJ Open, 2016, 6, e010704.	0.8	2
116	Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report. Journal of Medical Case Reports, 2020, 14, 201.	0.4	2
117	Is Heterozygosity for the Alpha-1 Antitrypsin Risk Allele Piâ^—MZ a Disease Modifier or Genetic Risk Factor?. Gastroenterology, 2020, 159, 433-434.	0.6	2
118	Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact. World Journal of Gastroenterology, 2021, 27, 2039-2053.	1.4	2
119	Using Infodemiology Metrics to Assess Public Interest in Liver Transplantation: Google Trends Analysis. Journal of Medical Internet Research, 2021, 23, e21656.	2.1	2
120	OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDAO4/05 Randomized Controlled Trials. Journal of the Endocrine Society, 2019, 3, .	0.1	2
121	Monitoring Iron Overload: Relationship between R2* Relaxometry of the Liver and Serum Ferritin under Different Therapies. Journal of Clinical Imaging Science, 2018, 8, 40.	0.4	2
122	Cloak and dagger ―secondary hemophygocytic lymphohistiocytosis caused by intravenous autoinfection. American Journal of Hematology, 2020, 95, 330-332.	2.0	1
123	Dual proteotoxic stress accelerates liver injury via activation of <scp>p62â€Nrf2</scp> . Journal of Pathology, 2021, 254, 80-91.	2.1	1
124	DOP89 Effects of ferric derisomaltose and ferric carboxymaltose on hypophosphatemia in iron-deficiency anaemia due to Inflammatory Bowel Disease: A Phase IV randomised clinical trial. Journal of Crohn's and Colitis, 2021, 15, S121-S121.	0.6	1
125	Response to Successful liver transplantation for hepatocellular carcinoma following downâ€staging using sorafenib single therapy by Borentain etÂal Liver International, 2016, 36, 1394-1394.	1.9	0
126	Reply. Liver Transplantation, 2019, 25, 344-345.	1.3	0

#	Article	lF	Citations
127	Reply. Liver Transplantation, 2019, 25, 1287-1288.	1.3	O
128	P723 Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with iron isomaltoside or ferric carboxymaltose: results of a prospective cluster randomised cohort study. Journal of Crohn's and Colitis, 2019, 13, S482-S483.	0.6	0
129	P6149Coronary computed tomographic angiography (CTA) for risk stratification in the diagnostic triage of patients undergoing liver transplantation (LT): A long-term outcome study. European Heart Journal, 2019, 40, .	1.0	0
130	Fatty Liver Disease: Metabolic, Genetic, or Both?. Hepatology Communications, 2020, 4, 1239-1241.	2.0	0
131	Quantification of hepatic liver iron overload with laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). , 2019, 57, .		0
132	Health Related Quality of Life and Healthcare Resource Utilization in chronic HCV patients under the Glecaprevir/Pibrentasvir Regimen: Interim-Analysis of the Austrian CONFIRMATION Study. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.2	0
133	High pre-test likelihood for non-HFE mutations through full exome sequencing in patients with hepatic iron overload. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.2	0
134	Bone marker response to intravenous iron treatment - an in vitro model. , 2021, 59, .		0
135	Update on the Austrian epidemiology of Hepatitis D Virus (HDV). , 2021, 59, .		0